What Happened
- The Union Budget 2026-27 (presented February 1, 2026) was shaped in part by the shadow of Trump's tariff threats — Finance Minister Sitharaman made strategic adjustments to customs duties and industrial policy across several sectors facing US pressure.
- The Budget expanded support for seven strategic and frontier manufacturing sectors: semiconductors, electronics components, biopharma, chemicals, capital goods, textiles, and footwear.
- Custom duties were reduced on select US-sensitive imports (industrial goods, some agricultural products) as pre-emptive concessions ahead of bilateral trade negotiations.
- Sectors most vulnerable to US retaliatory tariffs — gems and jewellery (~$9 billion US exports), electronics (~$14 billion US exports), pharmaceuticals (50% of US generic drug market), and agriculture — received targeted support measures.
- Pharmaceuticals and semiconductors were specifically exempted from reciprocal tariffs in the US framework announced on February 2, 2026 — reflecting India's strategic leverage in these sectors.
- The Budget's trade architecture signals a shift from purely defensive import substitution toward export competitiveness under a more transactional US trade relationship.
Static Topic Bridges
India's Industrial Policy: From Import Substitution to Strategic Manufacturing
India's industrial policy has evolved through several distinct phases, from post-independence import substitution to the current "supply chain security" era triggered by COVID-19 and US-China decoupling.
- Import Substitution Industrialisation (ISI): Dominant policy paradigm 1950s-1991, characterised by high tariffs, industrial licensing, and public sector dominance. Led by the Planning Commission and implemented through Industries Development and Regulation Act, 1951.
- 1991 Liberalisation: Industrial licensing abolished for most sectors; FDI opened; MRTP Act replaced by Competition Act (2002). Marked the transition to export-led growth orientation.
- Make in India (2014): Aimed at increasing manufacturing's share of GDP to 25% (from ~15%). Identified 25 sunrise sectors. Results have been mixed — manufacturing GDP share has not materially increased.
- Production Linked Incentive (PLI) Scheme (2020-21 onwards): The current generation of industrial policy. Offers incentives as % of incremental sales over a base year to manufacturers in targeted sectors. 14 sectors covered including mobile phones, pharmaceuticals, automobiles, textiles, food processing, semiconductors.
- Semiconductor Mission (2021): IndSemicon target — building India's first domestic semiconductor fabrication ecosystem, with TATA Electronics-Powerchip and CG Power-Renesas projects approved for chip fabs.
Connection to this news: Budget 2026-27's expansion to seven strategic sectors deepens PLI logic — the selection of semiconductors, biopharma, and electronics components directly addresses US concerns about supply chain over-dependence on China.
India's Pharmaceutical Trade: Strategic Leverage with the US
India's pharmaceutical sector is a specific case where trade vulnerability and strategic leverage coexist — making it a high-value subject for Mains GS3.
- India is the world's largest supplier of generic medicines, accounting for approximately 20% of global generic drug volume and 50% of US generic drug imports by volume.
- The US FDA has approved over 500 Indian manufacturing plants — more than from any other country outside the US.
- India's pharmaceutical exports exceed $27 billion annually (FY24), with the US being the single largest market (~30% of exports).
- The Indian pharmaceutical industry is regulated domestically by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940.
- Trump's tariff exemption for pharmaceuticals reflects US healthcare system dependency on Indian generics — removing this exemption would immediately raise drug prices for US consumers.
- India's pharmaceutical supply chain vulnerability: Active Pharmaceutical Ingredients (APIs) — the raw chemical inputs for drug manufacturing — rely heavily on Chinese imports (~68% API import dependence on China for certain categories).
Connection to this news: India's exemption from US pharmaceutical tariffs is not a concession — it reflects US strategic self-interest. Budget 2026-27's biopharma support aims to reduce India's own API import dependence on China, strengthening India's position as a reliable global supplier.
WTO Subsidies Discipline: Industrial Support in Trade Law
Government industrial support through PLI schemes, customs duty changes, and direct subsidies must navigate WTO disciplines on subsidies.
- WTO Agreement on Subsidies and Countervailing Measures (ASCM): Classifies subsidies into "prohibited" (export subsidies, import substitution subsidies — called "red light") and "actionable" (subsidies that may cause adverse effects — called "yellow light"). Non-actionable subsidies ("green light") were eliminated in 2000.
- Countervailing Duties (CVDs): WTO allows countries to impose CVDs on imports benefiting from foreign government subsidies if they cause material injury to domestic industry.
- PLI schemes offer incentives based on incremental production rather than export performance — deliberately designed to avoid classification as export subsidies under ASCM.
- Special Economic Zones (SEZs): India faced WTO challenges regarding its SEZ export incentives; the US filed a dispute (DS541) in 2018. India's SEZ Act, 2005 export benefits were found inconsistent with ASCM.
- Customs duty reductions: Reducing import duties is generally WTO-compatible and can signal openness to market access — the approach used in Budget 2026-27 for US-facing product categories.
Connection to this news: India's Budget 2026-27 customs duty reductions are WTO-compliant concessions (they apply on MFN basis), while PLI-based sector support is structured to avoid actionable subsidy classification — allowing India to both liberalise and subsidise within WTO disciplines.
India's Export Competitiveness: Gems, Jewellery, and Electronics
Two of India's largest export sectors to the US — gems & jewellery and electronics — were highlighted as vulnerable to Trump tariffs.
- Gems and Jewellery: India exports approximately $9 billion worth to the US annually. The sector employs ~5 million workers, mostly in Gujarat (diamonds) and Maharashtra (gold jewellery). The Gem and Jewellery Export Promotion Council (GJEPC) is the nodal export body.
- Electronics: India's electronics exports have grown sharply post-PLI — Apple (through Foxconn and Tata) now assembles iPhones in India, with significant exports to the US. Total electronics exports ~$14 billion to the US.
- Both sectors are labour-intensive — tariff protection directly affects employment in politically sensitive states.
- India's Labour Cost Advantage: India's manufacturing wages are broadly competitive with China (~$250-300/month), making it a viable alternative supply base for US companies.
- A 25% US tariff on Indian gems/jewellery would effectively eliminate India's price competitiveness against tariff-exempt countries.
Connection to this news: Budget 2026-27's sector-specific backing (production incentives, export credit, duty drawback improvements) aims to cushion these sectors from tariff vulnerability while diplomatic negotiations determine the final tariff regime.
Key Facts & Data
- Seven strategic manufacturing sectors supported in Budget 2026-27: Semiconductors, Electronics components, Biopharma, Chemicals, Capital goods, Textiles, Footwear
- India's pharmaceutical exports: ~$27 billion annually (FY24); US = ~30% of this
- India's share of US generic drug market: ~50% by volume
- India's pharmaceutical exports: ~500 US FDA-approved plants (most outside US globally)
- India's gems and jewellery exports to US: ~$9 billion annually
- India's electronics exports to US: ~$14 billion annually
- Indian pharmaceuticals API import dependence on China: ~68% for certain categories
- Trump's reciprocal tariff on India (Feb 2026): reduced from 25% to 18%
- Pharmaceutical and semiconductor sectors: exempted from US reciprocal tariffs
- PLI Scheme: 14 sectors, launched 2020-21; incentive = % of incremental sales over base year
- SEZ WTO dispute (DS541): US challenged India's export incentives; found inconsistent with ASCM
- India manufacturing share of GDP: ~15-16% (Make in India target: 25%)